
Pharmacally
gsk
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in gsk
Mergers & AcquisitionsGSK Acquires Nuvalent, Adding FDA-Reviewed ROS1 and ALK InhibitorsGSK has agreed to acquire Nuvalent in a $10.6B cash deal, securing FDA-reviewed NSCLC therapies zidesamtinib and neladalkib.Fact-Checked
Mergers & AcquisitionsGSK Licenses SiranBio’s siRNA Candidate SA030 in Up to $1 Billion DealGSK has signed a worldwide exclusive licensing agreement with Suzhou Siran Biotechnology for SA030, a Phase I long-acting siRNA therapy targeting ALK7 for metabolic and vascular disease, excluding…Fact-Checked
Mergers & AcquisitionsGSK’s Bold Lungstrike: Acquiring 35Pharma to Unleash HS235 on PHGSK completes its $950 million acquisition of 35Pharma, securing HS235, a next-generation activin pathway inhibitor with potential to address key safety gaps in pulmonary hypertension treatment.Fact-Checked
Health TidingsGSK’s Bepirovirsen Accepted by EMA for Review in Chronic Hepatitis BThe European Medicines Agency has accepted GSK plc’s filing for bepirovirsen in chronic hepatitis B, backed by Phase III B-Well trials demonstrating significantly higher functional cure rates versus…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.